Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

EMYLIF 50 MG PELICULA BUCODISPERSABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/EMYLIF 50 MG PELICULA BUCODISPERSABLE

Approved

STANDARD

EMYLIF 50 MG PELICULA BUCODISPERSABLE

Zambon S.P.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Apr 4, 2023
Approval ID: 8be4e76f6d2c5270
Company: Zambon S.P.A.
Type: Standard

Approval Details

Approval Id: 8be4e76f6d2c5270
Drug Cima Aemps Name: EMYLIF 50 MG PELICULA BUCODISPERSABLE
Register Number: 88570
Holder Company Name: Zambon S.P.A.
Marketing Company Name: Zambon S.A.U.
Authorization Date: 2023-04-04
Dosage Form: PELICULA BUCODISPERSABLE
Dose: 50 mg
Route Of Administration: VÍA ORAL
Prescription Type: Uso Hospitalario
Commercialized: Yes
Company Name: Zambon S.P.A.

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Apr 4, 2023

Approval ID

8be4e76f6d2c5270

Type

Standard

Back to CIMA-AEMPS Approvals